相关临床试验
0
0 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
1985
暂无试验阶段数据
暂无试验数据
暂无试验数据
暂无批准数据
- A 36-year-old father in Singapore reversed his hepatitis C and fatty liver disease through medication, diet, and exercise to become a viable living liver donor for his three-year-old son with Alagille syndrome. - Alagille syndrome, affecting approximately one in 70,000 people, is a rare genetic disorder where abnormal bile ducts cause liver damage, with liver transplantation being the only effective long-term treatment. - The complex 12-hour living donor liver transplant was performed on March 26 at National University Hospital, involving coordinated surgical teams from both adult and paediatric liver transplantation programmes. - The successful procedure transformed Isaiah from a jaundiced, frail toddler into an active child, while his father permanently adopted a healthier lifestyle post-donation.
- Singapore recorded 38 drug-linked traffic accidents between 2023 and 2025, with 19 fatalities, and etomidate implicated in 18 of 29 cases in 2025 alone. - Clinical toxicologist Dr. Jonathan Tang warns etomidate impairs reaction time, hazard perception, and vehicle control, comparable to alcohol intoxication. - A 34-year-old man faces dangerous driving causing death charges after a CTE crash that killed a 20-year-old motorcyclist, with etomidate detected in his blood. - Traffic deaths reached a 10-year high of 149 in 2025, with injuries rising from 9,342 to 9,955, prompting urgent calls for enhanced enforcement.
- A 16-year-old Singaporean boy diagnosed with lymphoma in October 2021 relapsed after six cycles of chemotherapy in June 2022. - CAR T-cell therapy, an experimental immunotherapy typically reserved for adults, was approved by the hospital ethics board and administered in October 2022. - The therapy, which has a 30% success rate in adults with relapsed lymphoma, produced a dramatic response with only mild side effects, enabling the patient to return to school within six months. - The Children's Cancer Foundation funded the CAR T-cell treatment, highlighting the role of charitable support in accessing advanced pediatric cancer therapies.
- Researchers from NIE NTU Singapore, SMART, MIT, NUH, and NUS Medicine developed the first optical nanosensor specifically designed to detect indole-3-propionic acid (IPA), a key gut health biomarker. - The dual-mode platform operates in visible fluorescence for rapid screening and near-infrared for potential in vivo and wearable applications, delivering results within minutes. - Validated in 125 human plasma samples, the sensor revealed significantly lower IPA levels in patients with active inflammatory bowel disease, including Crohn's disease and ulcerative colitis. - The team has been awarded an Innovation to Startup (I2Start) grant to incubate a proto-startup aimed at translating the sensor into a point-of-care clinical diagnostic tool.
- Genesis MedTech Group and the National University Health System have established a strategic partnership to advance artificial intelligence in surgery and medical device innovation through a two-phase, four-year program. - The collaboration will co-innovate AI projects in surgery, engage NUHS clinicians for stronger alignment between product development and clinical needs, and establish the "Genesis-NUHS AI Innovation and Surgical Training Lab." - The partnership adopts a design-led approach to translate unmet clinical needs into meaningful solutions, aiming to make surgery safer, smarter and more accessible to patients worldwide. - AI-driven technologies are enabling surgeons with data-driven insights to deliver safer, personalized outcomes while supporting hospitals in providing more cost-effective care.
- CytoMed Therapeutics has received full approval for its Phase I ANGELICA trial, evaluating allogeneic CAR-T cell therapy in advanced cancers. - The ANGELICA trial uses gamma delta T cells from healthy donors, potentially improving CAR-T cell quality and reducing production costs. - The trial is co-supported by the Singapore Ministry of Health through the National Medical Research Council (NMRC) and involves collaboration with the National University Hospital (NUH). - Part 2 of the ANGELICA trial will proceed with the recruitment of patients with advanced cancers resistant to standard therapy regimens.
- Researchers in Singapore have identified key molecular mechanisms driving gastric cancer's spread to the peritoneum, the most common site of metastasis. - The study pinpointed genetic alterations and characteristics within the tumor microenvironment (TME) that facilitate peritoneal metastasis. - A Phase I clinical trial (PIANO) combining PIPAC with immunotherapy showed promising results, with good tolerability and reduced tumor burden. - These findings pave the way for personalized treatment strategies and combination therapies targeting the TME to combat gastric cancer peritoneal metastases.
